Is the combination of bilateral pulmonary nodules and mosaic attenuation on chest CT specific for DIPNECH?

Bilal F. Samhouri1, Chi Wan Koo2, Eunhee S. Yi3 and Jay H. Ryu1*

Abstract

Background: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is characterized by multifocal proliferation of pulmonary neuroendocrine cells. On chest CT, DIPNECH exhibits bilateral pulmonary nodules and mosaic attenuation in most patients. We sought to: (1) assess the specificity of this pattern (i.e., bilateral pulmonary nodules together with mosaic attenuation) for DIPNECH; (2) describe its differential diagnosis; and (3) identify the clinico-radiologic features that may help prioritize DIPNECH over other diagnostic considerations.

Methods: We searched the Mayo Clinic records from 2015 to 2019 for patients with bilateral pulmonary nodules and mosaic attenuation on CT who had a diagnostic lung biopsy. A thoracic radiologist reviewed all CT scans. Chi-square test was used for categorical variables, and odds ratios were utilized to measure the association between certain variables and DIPNECH.

Results: Fifty-one patients met our inclusion criteria; 40 (78%) were females and 34 (67%) were never-smokers. Median age was 65 (interquartile range 55–73) years. Lung biopsy was surgical in 21 patients (41%), transbronchial in 17 (33%), and transthoracic in 12 (24%); explanted lungs were examined in 1 (2%). Metastatic/multifocal cancer was the most common diagnosis, and was found in 17 (33%) cases. Bronchiolitis was diagnosed in 12 patients (24%), interstitial lung disease in 10 (20%), and DIPNECH in 5 (10%). Previous diagnosis of an obstructive lung disease (odds ratio 15.8; \( P = 0.002 \)), and peribronchial nodular distribution on CT (odds ratio 14.4; \( P = 0.006 \)) were significantly correlated with DIPNECH. Although statistical significance was not reached, DIPNECH nodules were more likely to display solid attenuations (80% vs. 67%, \( P = 0.45 \)), and were more numerous; > 10 nodules were seen in 80% of DIPNECH cases vs. 52% in others (\( P = 0.23 \)). Because DIPNECH primarily affects women, we analyzed the women-only cohort and found similar results.

Conclusions: Various disorders can manifest the CT pattern of bilateral pulmonary nodules together with mosaic attenuation, and this combination is nonspecific for DIPNECH, which was found in only 10% of our cohort. Previous diagnosis of an obstructive lung disease, and peribronchial distribution of the nodules on CT increased the likelihood of DIPNECH vs. other diagnoses.

Keywords: DIPNECH, Pulmonary nodules, Mosaic attenuation

Introduction

Pulmonary neuroendocrine cells (PNECs) constitute <1% of the cells comprising adult human lungs [1]; they are scattered throughout both lungs, and can be seated in the bronchi, or in small airways (e.g., terminal bronchioles and alveolar ducts) [2]. Diffuse idiopathic
pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare entity that is characterized by abnormal, diffuse, and excessive proliferation of PNECs, and is considered by the World Health Organization as a precursor for other pulmonary neuroendocrine tumors (e.g., carcinoid tumors) [3]. DIPNECH has a strong predilection to affect middle-aged and elderly women, most of whom are never-smokers [4].

On computed tomography (CT) of the chest, DIPNECH exhibits bilateral pulmonary nodules in almost all affected individuals, and mosaic attenuation ("patchwork regions of differing attenuation") [5] in the majority [4]. Foci of hyperplastic PNECs, with or without carcinoid tumors/tumors, are responsible for the diffuse nodules, while constrictive bronchiolitis, which commonly accompanies DIPNECH, is responsible for air-trapping that manifests as mosaic attenuation on CT [4, 6, 7]. This CT pattern is considered the radiologic hallmark of DIPNECH [4, 8].

When DIPNECH is suspected, it can be challenging to confirm the diagnosis; transbronchial and transthoracic needle biopsies are often nondiagnostic, and securing the diagnosis frequently requires a surgical lung biopsy [4, 6], which is an invasive procedure that can be associated with significant morbidity and mortality [9]. This invites the obvious question: can DIPNECH be diagnosed non-invasively (i.e., without biopsy)? In order to answer this key question, we conducted this study with the following objectives: (1) measure the specificity of the CT pattern in-study (i.e., bilateral pulmonary nodules together with mosaic attenuation) for DIPNECH; (2) compare the clinic-radiologic features of patients with DIPNECH against those of patients with disorders other than DIPNECH; and accordingly, (3) formulate an algorithmic approach that aims to aid clinicians in prioritizing the diagnostic possibilities when encountered with the CT pattern in-study.

Methods
We searched the Mayo Clinic electronic medical records for the terms “mosaic attenuation”, “nodules” and “lung biopsy”. Patients must have had all of the following to meet our inclusion criteria: (1) having undergone a CT exam between 2015 and 2019; (2) demonstrating bilateral pulmonary nodules (excluding calcified nodules thought to represent granulomas) and mosaic attenuation on CT images; and (3) a diagnosis supported by lung biopsy.

To determine the eligibility of patients whose records were retrieved by our search terms, we first reviewed available CT and pathology reports. Patients were deemed eligible if they met all three inclusion criteria outlined above. Chest CT scans of eligible patients were subsequently reviewed by a fellowship-trained thoracic radiologist (C.W.K) with over 10 years of thoracic radiology experience, who re-interpreted all scans and recorded the following: the nodules’ number, density, and lobar and peribronchial distribution; the presence/absence of lung masses; the size of the largest nodule/mass seen; and the presence/absence of bronchial wall thickening. We did not attempt to distinguish between mosaic attenuation secondary to small airways disease vs. pulmonary vascular disease because making such distinction with certainty, though theoretically possible, can be rather challenging [10, 11].

Demographic, clinical, laboratory, pulmonary function and histopathological data were manually extracted. Chest CT scans and pulmonary function tests (PFTs) closest to the date of lung biopsy were selected. Because DIPNECH should be primarily suspected in women [4, 6, 7, 12], we also examined and characterized the women-only cohort.

On PFT, obstructive pattern was defined as forced expiratory volume in 1st second (FEV1)/forced vital capacity (FVC) < lower limit of normal (LLN); restrictive pattern was defined as total lung capacity (TLC) < LLN; mixed obstructive-restrictive pattern was defined as TLC < LLN and FEV1/FVC < LLN [13]; and nonspecific pattern was defined as FEV1 and/or FVC < LLN, with a normal FEV1/FVC ratio, and a TLC value that is ≥ LLN or unavailable [14]. Diffusing capacity of the lungs for carbon monoxide (DLCO) was considered abnormal if DLCO corrected for hemoglobin was < LLN. Air-trapping was defined as residual volume (RV) > 120% predicted, and hyperinflation as TLC > 120% predicted. A positive bronchodilator response was defined as an increase of ≥ 12% and ≥ 200 ml in FEV1 and/or FVC [13].

Frequencies and percentages were used for descriptive statistics. Median and interquartile range (IQR) were used as measures of central tendency. Chi-square test was used for categorical variables. Odds ratios (OR) with 95% confidence intervals (CI) were used to measure the association between different variables and a histopathological diagnosis of DIPNECH. Statistical significance was defined as P-value < 0.05. This study was approved by the Mayo Clinic Institutional Review Board.

Results
Our search terms yielded 141 patients. Ninety patients did not meet our inclusion criteria and were excluded; 28 (31%) had no lung biopsy or a nondiagnostic lung biopsy, whereas 62 (69%) failed to meet our CT inclusion criteria (e.g., unilateral nodules, one nodule only, mosaic attenuation and nodules were not simultaneously present). Fifty-one patients were included in the final analysis; 40 (78%) were women and 11 (22%) were men, with a median age
of 64 [IQR 56–73] years (Table 1). Most patients were white (94%), and never-smokers (67%).

Past medical history included a previous diagnosis of cancer in 16 patients (31%), autoimmune disease in 6 (12%), and pulmonary hypertension (PH) in 2 (4%); 4 patients were lung transplant recipients. Also, 7 patients (14%) had been previously diagnosed with an obstructive lung disease; asthma in 5, and chronic obstructive pulmonary disease (COPD) in 2.

Twenty-six patients (51%) presented for evaluation of chronic respiratory symptoms namely, dyspnea, cough, or both; median duration of symptoms prior to lung biopsy was 16 [IQR 4–72] months (Table 2). On the other hand, 4 patients (8%) were lung transplant recipients undergoing regular post-transplant surveillance, and 21 (41%) were evaluated for abnormalities noted on radiologic studies performed for other indications. PFT results were available for 43 patients; 4 were lung transplant recipients. Because normal values are based on the recipient’s, rather than the donor’s characteristics (age, height, gender and ethnicity) [13], we only analyzed PFT data belonging to the 39 patients without histories of lung transplantation; PFT was abnormal in 69% of cases, and the degree of respiratory impairment was mild to moderate in the majority (71%). Notably, air-trapping was present in only 10 (32%) of 31 patients with RV measurements.

Lung biopsy was surgical in 21 patients (41%), transbronchial in 17 (33%), and transthoracic (CT-guided) in 12 (24%); histopathological examination was performed on explanted lungs in 1 patient (2%). Histopathology-based diagnoses yielded six broad categories (Table 3): multifocal/metastatic cancer (33%), bronchiolitis (24%), interstitial lung disease (ILD) (20%), DIPNECH (10%), infection (6%), and “other” (8%). Of note, of 17 cancers, 7 (41%) were of pulmonary origin and 10 (59%) were of an extra-pulmonary origin. Although our aim was to calculate the specificity of the CT pattern in-study for DIPNECH, the small number of DIPNECH cases (N = 5) hindered our ability to do so. As such, we will use the term “prevalence” instead of “specificity” hereafter.

On CT, DIPNECH exhibited a higher number of nodules than other diagnoses, with > 10 nodules in 80% of patients with DIPNECH compared to 52% in others (P = 0.23) (Table 4). Also, DIPNECH nodules were more likely to exhibit a peribronchial distribution than others (80% vs. 22%, P = 0.006; OR 14.4 [CI 1.4–144]). Among patients whose nodules exhibited a peribronchial distribution, the prevalence of DIPNECH was 29% (P = 0.07). Furthermore, DIPNECH nodules were more likely to exhibit solid attenuations (80% vs. 67%, P = 0.45). Bronchial wall thickening was seen in all patients with DIPNECH, but only 67% of patients with other diagnoses (P = 0.13). In our cohort, 5 patients (10%) had ≥ 1 lung mass (i.e., lesions > 3 cm in diameter) [5], none of whom had DIPNECH. The CT features of each of the six diagnostic categories are depicted in Additional file 1: Table S1.

When the data analysis was limited to the women-only cohort (N = 40), median age was 64 [IQR 56–72] years, most were white (98%), and 65% were never-smokers (Table 1). Past medical history included a previous diagnosis of cancer in 8 patients (20%), autoimmune disease in 6 (15%), an obstructive lung disease in 7 (18%), and PH in 2 (5%); 2 were lung transplant recipients. Among women, multifocal/metastatic cancer remained the most common diagnostic category (30%), followed by bronchiolitis (25%), ILD (20%), DIPNECH (13%), infection (5%), and “other” (8%) (Table 3). Six (50%) of the 12 cancers diagnosed in women were of pulmonary origin, all of which were adenocarcinomas.

Several observations underscore the value of the clinical context including the past medical history in the diagnostic evaluation of patients exhibiting the CT pattern in-study. In our cohort, a previous diagnosis of an obstructive lung disease (i.e., asthma or COPD)

---

Table 1 Patient characteristics of the entire cohort (N = 51) and the women-only cohort (N = 40)

| Characteristic                | Entire cohort | Women-only |
|------------------------------|---------------|------------|
|                             | N = 51        | N = 40     |
| Female sex                   | 40 (78)       | 40 (100)   |
| Age at diagnosis (years); median (IQR) | 65 (55–73)   | 64 (56–72) |
| Ethnicity White              | 48 (94)       | 39 (98)    |
| Ethnicity Other              | 3 (6)         | 1 (2)      |
| Smoking status Never         | 34 (67)       | 26 (65)    |
| Smoking status Previous      | 14 (27)       | 12 (30)    |
| Smoking status Current       | 3 (6)         | 2 (4)      |
| Past medical history Asthma and/or COPD | 7 (14)       | 7 (18)     |
| Past medical history Pulmonary hypertension | 2 (4)       | 2 (5)     |
| Past medical history Previous diagnosis of cancer | 16 (31) | 8 (20) |
| Past medical history Previous diagnosis of autoimmune disease | 6 (12) | 6 (15) |
| Lung transplant recipient    | 4 (8)         | 2 (5)      |
| Lung biopsy method Surgical  | 21 (42)       | 14 (35)    |
| Lung biopsy method Bronchoscopic | 17 (33)     | 14 (35)    |
| Lung biopsy method Transthoracic (i.e., CT-guided) | 12 (24) | 11 (28) |
| Lung biopsy method Explanted lungs | 1 (2)       | 1 (3)      |

Data are presented as N (%) unless otherwise specified
IQR interquartile range, COPD chronic obstructive pulmonary disease, CT computed tomography
was more commonly encountered among patients with DIPNECH (60% vs. 9%, \( P = 0.002 \)), and the presence of such history significantly correlated with an eventual diagnosis of DIPNECH on histopathology (OR 15.8 [CI 2.0–124]). Importantly, this correlation retained statistical significance in the women-only cohort as well (\( P = 0.008 \)).

Of 12 women in whom lung biopsy showed multifocal/metastatic cancer, 8 (67%) had a known history of cancer when the CT abnormalities were identified; in the 4 remaining women, metastatic/multifocal lung adenocarcinoma was diagnosed in 3, and lymphoma in 1. Further, both women with an infectious etiology were known to be taking immunosuppressive medications,

### Table 2

Presenting symptoms and pulmonary function data across the entire cohort (N = 51) and the women-only cohort (N = 40)

| Presenting symptom(s) | Entire cohort (N = 51) | Women-only (N = 40) |
|-----------------------|-----------------------|---------------------|
| Cough                 | 6 (12)                | 5 (13)              |
| Cough and dyspnea     | 7 (14)                | 6 (15)              |
| Wheezing              | 1 (2)                 | 1 (3)               |
| Hemoptysis            | 1 (2)                 | 1 (3)               |
| Dyspnea               | 11 (22)               | 10 (25)             |
| Post-transplant surveilance | 4 (8) | 2 (5) |
| Incidental CT findings| 21 (41)               | 15 (38)             |

**Duration of respiratory symptoms, months**

| Median [IQR] |
|--------------|
| 16 [4–72]    |
| 19 [4–72]    |

**Pulmonary function testing**

| PFT pattern | Entire cohort (N = 39) | Women-only (N = 33) |
|-------------|------------------------|---------------------|
| Normal      | 12 (31)                | 11 (33)             |
| Obstructive | 10 (26)                | 9 (27)              |
| Restrictive | 11 (28)                | 7 (21)              |
| Mixed       | 0 (0)                  | 0 (0)               |
| Nonspecific | 6 (15)                 | 6 (18)              |

**Severity of respiratory impairment**

| \( \geq 70\% \) predicted | Entire cohort (N = 27) | Women-only (N = 22) |
|-----------------------------|------------------------|---------------------|
| \( 60–69\% \) predicted    | 11 (41)                | 8 (36)              |
| \( 50–59\% \) predicted    | 8 (30)                 | 7 (32)              |
| \( 35–49\% \) predicted    | 3 (11)                 | 3 (14)              |
| \( < 35\% \) predicted     | 3 (11)                 | 2 (9)               |

**Air trapping and hyperinflation**

| Entire cohort (N = 31) | Women-only (N = 26) |
|------------------------|---------------------|
| Air trapping present   | 10 (32)             | 9 (35)              |
| Hyperinflation present | 3 (10)              | 3 (12)              |

**Diffusing capacity**

| Entire cohort (N = 31) | Women-only (N = 26) |
|------------------------|---------------------|
| DLCO reduced           | 15 (48)             | 12 (46)             |
| Degree of DLCO reduction (% predicted); median [IQR] | 51 [48–61] | 50 [45–61] |

**Bronchodilator responsiveness**

| Entire cohort (N = 26) | Women-only (N = 22) |
|------------------------|---------------------|
| Positive BD response   | 5 (19)              | 5 (23)              |
| Negative BD response   | 21 (81)             | 17 (77)             |

---

Data are presented as N (%) unless otherwise specified

CT computed tomography, IQR interquartile range, PFT pulmonary function test, FEV1 forced expiratory volume in 1st second, DLCO diffusing capacity of carbon monoxide, BD bronchodilator

* Excluding the 4 lung transplant recipients

† Severity is determined by FEV1% of predicted value
and both women with history of lung transplantation were ultimately diagnosed with bronchiolitis obliterans syndrome.

Four women were diagnosed with follicular bronchiolitis in our cohort. When the CT pattern in-study was identified in these patients, all had been known to have history of autoimmunity; 1 patient had scleroderma, 1 had rheumatoid arthritis (RA), and the other 2 were known to have persistently elevated titers of various autoantibodies (antinuclear, anti-Scl70 and anti-CCP antibodies in one, and anti-RNP antibodies in one). Similarly, the woman with rheumatoid lung nodules had been diagnosed with RA several years preceding the CT abnormalities.

Two patients in our cohort had PH which, similar to air-trapping, can manifest mosaic attenuation on chest CT [10]. Both patients manifested PFT abnormalities (airflow obstruction in one, and nonspecific pattern with air-trapping in the other), and were ultimately diagnosed with sarcoidosis and follicular bronchiolitis, respectively. We believe that, in both patients, the mosaic attenuation observed is at least partly related to air-trapping and may not be solely attributed to PH.

Lastly, the patient with a usual interstitial pneumonia (UIP) pattern on histopathology had a CT pattern that is “indeterminate for UIP” owing to the degree of bronchocentric fibrosis. This patient was also found to have elevated autoantibody titers; in particular, antinuclear, anti-U1 RNP, and anti-NXP-2 antibodies.

Discussion
This is the first study to examine the prevalence of DIPNECH among patients exhibiting the CT pattern that is considered the radiologic hallmark of DIPNECH, i.e., bilateral pulmonary nodules combined with mosaic attenuation. We found that the prevalence of DIPNECH was only 10% in our cohort, and that this CT pattern can be encountered in the context of a broad array of disorders including: metastatic/multifocal cancer, bronchiolitis, ILD, atypical infections, and autoimmune/connective tissue diseases (CTDs). Interestingly, individuals who had a previous diagnosis of an

Table 3 The diagnoses included under the six broad diagnostic categories, with their frequencies across the entire cohort (N = 51) and the women-only cohort (N = 40)

| Diagnostic categories                                      | Entire cohort N = 51 | Women-only N = 40 |
|-----------------------------------------------------------|----------------------|-------------------|
| Cancer                                                    | 17 (33)              | 12 (30)           |
| Metastatic/multifocal lung adenocarcinoma                  | 6 (12)               | 6 (15)            |
| Metastatic lung cancer (subtype other than adenocarcinoma) | 1 (2)                | 0 (0)             |
| Metastatic adenocarcinoma of unknown primary               | 1 (2)                | 1 (3)             |
| Metastatic cancer with primary other than lung             | 7 (14)               | 4 (10)            |
| Hematological malignancy                                  | 2 (4)                | 1 (3)             |
| Bronchiolitis                                             | 12 (24)              | 10 (25)           |
| Bronchiolitis obliterans in lung transplant recipient     | 4 (8)                | 2 (5)             |
| Bronchiolitis obliterans in non-lung transplant recipient  | 3 (6)                | 3 (8)             |
| Follicular bronchiolitis                                  | 4 (8)                | 4 (10)            |
| Respiratory bronchiolitis                                 | 1 (2)                | 1 (3)             |
| Interstitial lung disease                                 | 10 (20)              | 8 (20)            |
| Hypersensitivity pneumonitis                              | 7 (14)               | 7 (18)            |
| Cicatrical COP                                            | 1 (2)                | 0 (0)             |
| PLCH                                                       | 1 (2)                | 1 (3)             |
| UIP                                                       | 1 (2)                | 0 (0)             |
| DIPNECH                                                   | 5 (10)               | 5 (13)            |
| Infection                                                 | 3 (6)                | 2 (5)             |
| Fungal infection                                          | 2 (4)                | 1 (3)             |
| Nontuberculous mycobacteria                               | 1 (2)                | 1 (3)             |
| Other                                                     | 4 (8)                | 3 (8)             |
| Rheumatoid nodules                                        | 1 (2)                | 1 (3)             |
| Sarcoidosis nodules                                       | 3 (6)                | 2 (5)             |

Data are presented as N (%)
patients with other diagnoses:

**NECH from other diagnoses.**

an algorithmic approach (Fig. 1) that integrates clinical and radiologic findings suggestive of DIPNECH.

Historical manifestations tend to appear later in the course of a known CTD, rather than as the initial presenting features of an extrapulmonary origin, however, respiratory symptoms are usually absent, and systemic symptoms dominate instead [16].

In patients with primary lung cancer, the interval between symptom onset and diagnosis is noticeably shorter than in DIPNECH, and is on the order of weeks to months [15]. In patients with pulmonary metastases of an extrapulmonary origin, however, respiratory symptoms are usually absent, and systemic symptoms dominate instead [16].

DIPNECH is seldom associated with systemic symptoms (e.g., loss of appetite, weight loss, fever, night sweats), and aside from metastatic cancers, this also contrasts disseminated fungal infections wherein such symptoms are frequently encountered [16, 17]. In contrast to CTDs, atypical infections, and metastatic cancers, all of which commonly involve other organ systems, DIPNECH, per se, is strictly limited to the lungs. An exception to this rule, however, is when DIPNECH is complicated by metastatic carcinoid tumor [4, 6]. While DIPNECH is typically encountered in nonsmokers, some of the other diagnostic considerations included herein affect smokers almost exclusively (e.g., pulmonary Langerhans cell histiocytosis (PLCH) and respiratory bronchiolitis) [18, 19].

In our women-only cohort, all patients with CTD-associated respiratory manifestations, particularly follicular bronchiolitis and rheumatoid nodules, had been known to have underlying autoimmune disease prior to their diagnostic evaluation. This is concordant with previous studies which showed that CTD-associated respiratory manifestations tend to appear later in the course of a known CTD, rather than as the initial presenting features of a previously-undiagnosed CTD [20–22].

Having a history of cancer in an individual manifesting multiple pulmonary nodules on CT should prompt consideration that these nodules are cancerous until proven otherwise. This proposition is supported by our study; most women who were diagnosed to have metastatic/carcinomatous lung disease, and those in whom the pulmonary nodules exhibited a peribronchial distribution were more likely to have DIPNECH.

Our cohort predominantly comprised middle-aged and elderly women, most of whom were never-smokers; many presented with chronic respiratory symptoms, namely dyspnea, cough, or both. These patient characteristics are reminiscent of those typically affected by DIPNECH [4, 6, 7, 12]. Accordingly, the present study is well-positioned to elucidate the alternative diagnoses that should be considered in patients presenting with clinical and radiologic findings suggestive of DIPNECH.

Our data suggest that the CT pattern under-study is nonspecific for DIPNECH and although meticulous examination of the CT images may narrow down the diagnostic possibilities, it cannot be diagnostic without carefully considering the clinical context and the radiologic evolution of the nodules over time. While a comprehensive discussion relating to the clinical and radiologic features of each differential diagnosis is beyond the scope of this paper, we will highlight certain high-yield features and propose an algorithmic approach (Fig. 1) that integrates clinical and radiologic data and might prove helpful in distinguishing DIPNECH from other diagnoses.

The importance of accurately assessing the clinical context through careful history-taking cannot be overstated. Limited awareness of DIPNECH as an entity among clinicians and radiologists, complicated by the nonspecific symptomatology of DIPNECH have led to substantial delays (a decade or more in 50–60% of patients) [4, 6] and errors in its diagnosis; nearly one-half of patients in previous studies [4, 6, 7], and 60% in the present study had their respiratory syndromes erroneously attributed to asthma and/or COPD before a final diagnosis of DIPNECH was attained. In the present study, patients with DIPNECH were significantly more likely to have been misdiagnosed as asthma or COPD. In other words, in patients with bilateral pulmonary nodules and mosaic attenuation on CT, carrying a diagnosis of asthma or COPD renders an eventual diagnosis of DIPNECH more likely.

**Table 4** Chest CT scan findings in patients with DIPNECH vs. patients with other diagnoses

| Characteristic                | DIPNECH N = 5 | Other diagnoses N = 46 |
|------------------------------|---------------|------------------------|
| Number of nodules            |               |                        |
| 2–3                         | 0 (0)         | 7 (15)                 |
| 4–5                         | 0 (0)         | 3 (7)                  |
| 6–10                        | 1 (20)        | 12 (26)                |
| > 10                        | 4 (80)        | 24 (52)                |
| Nodule density               |               |                        |
| Solid only                   | 4 (80)        | 29 (63)                |
| Solid and subsolid†          | 1 (20)        | 17 (37)                |
| Lobar predominance           |               |                        |
| Upper lobes                  | 0 (0)         | 3 (7)                  |
| Lower lobes                  | 0 (0)         | 2 (4)                  |
| Random                       | 5 (100)       | 41 (89)                |
| Peribronchial distribution** | 4 (80)        | 10 (22)                |
| Bronchial wall thickening    | 5 (100)       | 31 (67)                |
| Masses present               | 0 (0)         | 5 (11)                 |
| Diameter of largest nodule/mass (mm); median (range) | 7 (4–30) | 8 (3–69) |

Data are presented as N (%) unless otherwise specified

DIPNECH: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
† Subsolid attenuations include ground-glass, and part-solid attenuations
** Signifies p-value < 0.05

DIPNECH: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
† Subsolid attenuations include ground-glass, and part-solid attenuations
** Signifies p-value < 0.05
Fig. 1 Algorithmic approach towards CT scans depicting bilateral pulmonary nodules and mosaic attenuation. Abbreviations: CT: Computed tomography, CTD: connective tissue disease, DIPNECH: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, HP: hypersensitivity pneumonitis, PLCH: pulmonary Langerhans cell histiocytosis.
multifocal cancer had a previous diagnosis of cancer. Furthermore, in one study that included 228 patients with one or more pulmonary nodule(s) and a previous diagnosis of an extrapulmonary malignancy, cancer was found in 90% of lung biopsies; 64% were metastatic, and 26% were primary lung cancers [23]. In the same study, compared to a single nodule, the presence of multiple nodules further increased the likelihood that those nodules represented metastases. It is prudent to keep in mind that although a history of cancer is present in most patients with pulmonary metastases, such history may be lacking in some cases, and pulmonary metastases can be encountered as the initial manifestation of a previouslyundiagnosed malignancy [24].

In terms of the characteristics of the nodules themselves, the present study found that DIPNECH nodules exhibit a solid attenuation in most cases. According to Carr et al., DIPNECH nodules are well-defined, round or oval in shape, rarely calcified, and noncavitary (Fig. 2a) [6]. These features are grossly disparate from HP and respiratory bronchiolitis whose nodules are subsolid, hazy and ill-defined (Fig. 2b) [25, 26]. The recognition of spiculated margins, and/or cystic or cavitary components within the nodules favors a diagnosis of cancer [27–30]. In addition to malignancies, cavitary nodules can be seen in association with fungal infections and RA [22, 31].

In DIPNECH, the majority of nodules are 6–10 mm in diameter [6]. This differs from HP, bronchiolitis and sarcoidosis, wherein micronodules (i.e., nodular opacities ≤3–7 mm in diameter) [5] are dominant [25, 26]. Notably, lung masses are rarely encountered in DIPNECH [4], and when present, they likely represent carcinoid tumors. In a study that included 32 patients with DIPNECH, only 1 lung mass was found [7]. While identifying one lung mass does not rule out DIPNECH, identifying multiple masses should invite serious consideration of an alternative diagnosis. In the present study, 5 patients had at least one lung mass, none of whom had DIPNECH.

Based on the present study, a peribronchial distribution of the nodules appears to be the CT feature most predictive of DIPNECH, when occurring in combination with mosaic attenuation. In the present study, we found that DIPNECH nodules exhibit a random craniocaudal distribution. Conversely, two larger studies reported that DIPNECH nodules display an affinity to involve lower- and mid-lung zones [6, 7]. Nonetheless, such distribution differs from HP and sarcoidosis where upper- and mid-lung zones are preferentially involved [25, 32].

**Fig. 2** Illustrative chest CT scans. A Depicts a chest CT scan obtained from a 69 year-old female with DIPNECH. Note the solid and round nodule with smooth and well-defined margins (red arrow), in addition to pronounced mosaic attenuation. B Depicts a chest CT scan obtained from a 69 year-old female with respiratory bronchiolitis. Note the centrilobular, subsolid, hazy and ill-defined micronodules (yellow arrows), in addition to mosaic attenuation.
On CT, metastatic cancers with hematogenous seeding of the lungs classically appear as nodular lesion(s) that can be single to innumerable, and can range from few millimeters to several centimeters in size. Typically, these nodules are of solid attenuation, round in shape with smooth and well-defined borders, and are mostly non-calcified and noncavitary. Also, they favor peripheral and lower lung zones [28, 29]. These radiologic features are similar, to a large extent, to DIPNECH [6]; consequently, making the distinction between DIPNECH and pulmonary metastases solely on the basis of chest CT may not be possible.

Like DIPNECH, multifocal adenocarcinoma (MAC) of the lung primarily affects nonsmoker women, and manifests multiple, slowly-progressive pulmonary nodules that can be centered around the airways, with a predilection to involve peripheral lung zones [33]. However, two key features help distinguish MAC from DIPNECH; in MAC, the nodules are considerably less in number, and more likely to exhibit subsolid attenuations. In the study by Nakata et al., 31 patients with MAC had a total of 68 nodules on CT, only 19 (28%) of which were solid [34]. In another study, 39 patients with MAC had 149 nodules on CT, averaging 3.8 nodules per patient [35].

Multiple parenchymal cysts, extensive pulmonary fibrosis, diffuse ground-glass opacities, pleural effusions, and prominent intra- or extra-thoracic lymphadenopathy are very unusual findings in DIPNECH [4, 6, 7], and their presence urges considering alternative diagnoses, such as PLCH (parenchymal cysts), HP (fibrosis and ground-glass opacities), sarcoidosis (fibrosis and lymphadenopathy), infections, and malignancies (lymphadenopathy and pleural effusions).

Whenever previous imaging is available, comparison to assess the temporal evolution of the nodules over time is necessary. In the study by Little et al., 30 patients with DIPNECH had their initial and follow-up chest CT scans reviewed; over a median interval of 3.4 years, no growth was noted in the dominant nodule in one-third of cases, whereas slight growth (mean increase in size was 3.6 mm) was noted in the remainder two-thirds [7]. In view of this rather indolent nature, a rapid increase in the number and/or size of pulmonary nodules renders DIPNECH highly unlikely, and is more consistent with an infectious, inflammatory, or malignant etiology [36].

On CT imaging, mosaic attenuation is most commonly observed in the context of disorders that involve the small airways, such as primary bronchiolitides, in addition to certain ILDs, infections, and CTD-related manifestations (e.g., sarcoidosis nodules) [10]. In our study, however, metastatic/multifocal cancer was the most prevalent diagnosis. This observation is not entirely surprising because: (1) cancer may originate from cells situated within the small airways (e.g., lung adenocarcinoma) [37]; and (2) intra-airway metastasis from pulmonary and extra-pulmonary origins is a well-documented, though rare, phenomenon [30]. Although the mosaic attenuation seen in those patients with cancer may be secondary to another respiratory disorder, such possibility seems unlikely since none of them had been diagnosed with a chronic lung disease.

Our study has limitations. Requiring a lung biopsy for inclusion may have excluded patients with common disorders and those with classic CT appearances in whom the diagnosis could be established noninvasively. The previous notion, compounded by the referral nature of our center may have resulted in under-representation of common disorders, and over-representation of rare disorders, including DIPNECH. As a result, our study may have overestimated the specificity of the pattern in-study for DIPNECH. Finally, the modest sample size may have hindered our ability to achieve statistical significance in some instances.

Conclusion

The CT pattern, bilateral pulmonary nodules together with mosaic attenuation, is nonspecific for DIPNECH and can be seen in a myriad of disorders. Although the prevalence of DIPNECH in our cohort was low (10%), it may still be an overestimation owing to the referral nature of our center in addition to our inclusion criteria that necessitated lung biopsy. Amongst individuals manifesting the CT pattern in-study, the likelihood of DIPNECH increases if a previous diagnosis of an obstructive lung disease is present, and if the nodules exhibit a peribronchial distribution. Careful assessment of the clinical context, in addition to the morphology, distribution, and temporal evolution of the nodules helps prioritize the diagnostic possibilities. In very select circumstances, such linic-radiologic evaluation may be sufficiently suggestive of DIPNECH, potentially obviating the need for lung biopsy.

Abbreviations

COPD: Chronic obstructive pulmonary disease; CT: Computed tomography; CTD: Connective tissue disease; CI: Confidence interval; DIPNECH: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia; DLCO: Diffusing capacity of the lungs for carbon monoxide; FEV1: Forced expiratory volume in 1st second; FVC: Forced vital capacity; HP: Hypersensitivity pneumonitis; ILD: Interstitial lung disease; IQR: Interquartile range; IRB: Institutional review board; LLN: Lower limit of normal; MAC: Multifocal adenocarcinoma; OR: Odds ratio; PFT: Pulmonary function test; PH: Pulmonary hypertension; PLCH: Pulmonary Langerhans cell histiocytosis; PNEC: Pulmonary neuroendocrine cell; RA: Rheumatoid arthritis; RV: Residual volume; TLC: Total lung capacity; UIP: Usual interstitial pneumonia.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13023-021-02103-w.

Additional file 1. Chest CT scan findings divided by diagnostic category across the entire cohort (n = 51).

Acknowledgements
Not applicable.

Authors’ contributions
BFS, CWK, ESY, and JHR contributed substantially to the study design, data collection and interpretation, and the writing of the manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The data that support the findings of this study are available from Mayo Clinic but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Mayo Clinic’s IRB.

Declarations

Ethics approval and consent to participate
Consent was waived by the Mayo Clinic’s Institutional Review Board (IRB). The Mayo Clinic IRB approved this study (IRB# 17-000885).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Gonda 18 South, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. 2Department of Radiology, Mayo Clinic, Rochester, MN, USA. 3Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.

Received: 7 July 2021 Accepted: 27 October 2021 Published online: 22 November 2021

References
1. Boers JE, Den Brok JLM, Koudstaal J, Arends JW, Thunnissen FBJM. Number and proliferation of neuroendocrine cells in normal human airway epithelium. Am J Respir Crit Care Med. 1996;154:758–63.
2. Gosney JR, Sissoms MCI, Alibone RD. Neuroendocrine cell populations in normal human lungs: a quantitative study. Thorax. 1988;43:878–82.
3. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J Thorac Oncol. 2015;10:1243–60.
4. Samhouri BF, Azadeh N, Halfdannarson TR, Yi ES, Ryu JH. Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. ERJ Open Res Eur Respir Soc. 2020;6:00527–2020.
5. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J, Fleischner Society: Glossary of terms for thoracic imaging. Radiology. 2008. p. 697–722.
6. Carr LL, Chung JH, Achcar RD, Lescz 2, Rho JY, Yaghzhashi K, et al. The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Chest Am Coll Chest Phys. 2015;147:415–22.
7. Little BP, Junn JC, Zheng KS, Sanchez FW, Henry TS, Veeraraghavan S, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: imaging and clinical features of a frequently delayed diagnosis. Am J Roentgenol; 2020;215:1312–20.
8. Chassagnon G, Favelle O, Marchand-Adam S, De Muret A, Revel MP. DPI-NECH: when to suggest this diagnosis on CT. Clin. Radiol. 2015. p. 317–25.
9. Hutchinson JR, Fogarty AW, McKeever TM, Hubbard RB. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am J Respir Crit Care Med. 2016;193:1161–7.
10. Kligeman SJ, Henry T, Lin CT, Franks TJ, Galvin JR. Mosaic attenuation: etiology, methods of differentiation, and pitfalls. Radiographics.; 2015;35:1360–80.
11. Stern1 EJ, Frank MS. Small-airways diseases of the lungs: findings at expiratory CT. AJR. 1994.
12. Nassar AA, Jaroszewski DE, Helmers RA, Colby TV, Patel BM, Mockadam F. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview. Am J. Respir Crit. Care Med. 2011. p. 8–16.
13. Pellegrino R, Vegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68.
14. Iyer VN, Schroeder DR, Parker KO, Hyatt RE, Scalon PD. The nonspecific pulmonary function test: longitudinal follow-up and outcomes. Chest Am Coll Chest Phys. 2011;139:878–86.
15. Weller DP, Peake MD, Field JK. Presentation of lung cancer in primary care. npg Prim. Care Respir Med., 2019.
16. Hamilton W, Barrett J, Stapley S, Sharp D, Rose P. Clinical features of meta-
static cancer in primary care: a case-control study using medical records. Br J Gen Pract. 2015;65:e516–22.
17. Boyars MC, Zwischenberger JB, Cox CS. Clinical manifestations of pulmonary fungal infections. J Thorac Imaging J Thorac Imaging. 1992;7:12–22.
18. Suri HS, Yi ES, Nowakowski GS, Vassallo R. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis. 2012. p. 16.
19. Sieminska A, Kuziemski K. Respiratory bronchiolitis-interstitial lung disease. Orphanet J. Rare Dis. 2014. p. 106.
20. Tahrouss B, Okafor NC, Ramirez JF, Smolley L. Follicular bronchiolitis: a literature review. J. Clin. Diagnostic Res. 2013. p. OE01–5.
21. Stojan G, Baer AN, Danoff SK. Pulmonary manifestations of Sjögren’s syndrome. Curr Allergy Asthma Rep. 2013;13:354–60.
22. Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015.24;11–16.
23. Caparica R, Mak MP, Rocha CH, Velho PHI, Viana P, Moura MRL, et al. Pulmonary nodules in patients with nonpulmonary cancer: not always metastases. J Glob Oncol. 2016;2:138–44.
24. Jamil A, Kasi A. Cancer, Metastasis to the Lung. StatPearls. StatPearls Publishing, 2020.
25. Silva C1S, Chung A, Müller NL. Hypersensitivity pneumonitis: Spectrum of high-resolution CT and pathologic findings. Am. J. Roentgenol. AJR 2007. p. 334–44.
26. Winningham PJ, Martínez-Jiménez S, Rosado-de-Christenson ML, Beltr-
court SL, Restrepo CS, Eraso A. Bronchiolitis: a practical approach for the general radiologist. Radiographics.; 2017;37:777–94.
27. Pascoe HM, Knipe HC, Pascoe D, Heinze SB. The many faces of lung adenocarcinoma: a pictorial essay. J Med Imaging Radiat Oncol. 2018;62:651–61.
28. Hirakata1 N, Nakat1 H, Haratake2 J. Appearance of pulmonary metastases on high-resolution CT scans: comparison with histopathologic findings from autopsy specimens.
29. Davis SD. CT evaluation for pulmonary metastases in patients with extrathoracic malignancies. Radiology. 1991. p. 1–12.
30. Seo JB, Im JG, Goo JM, Chung MJ, Kim MY. Atypical pulmonary metastases: Spectrum of radiologic findings. Radiographics. 2001;21:403–17.
31. Orlowski HLP, McWilliams S, Mellnick VM, Bhalla S, Lubner MG, Pickhardt PJ, et al. Imaging spectrum of invasive fungal and fungal-like infections. Radiographics. 2017;37:1119–34.
32. Nunes H, Uzunhan Y, Gille T, Lomberto C, Valeyre D, Brillet PY. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. Eur. Respir. 2012. p. 750–65.
33. Austin JHM, Gang K, Abeerbe D, Yankelevitz D, Kuriyama K, Lee H-J, et al. Radiologic implications of the 2011 Classification of adenocarcinoma of the Lung 1. Radiology. 2013;266.
34. Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg. 2004;78:1194–9.

35. Mooradian M, Price MC, Muzikansky A, Lennes IT, Lanuti M, Willers H, et al. Multifocal adenocarcinoma of the lung: factors predictive for local therapy. J Clin Oncol. 2017;35:e20041–e20041.

36. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017. p. 228–43.

37. Fukui T, Shaykhiev R, Agosto-Perez F, Mezey JG, Downey RJ, Travis WD, et al. Lung adenocarcinoma subtypes based on expression of human airway basal cell genes. Eur Respir J. 2013;42:1332–44.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.